Jóri B, Vössing C, Pirngruber J, Willing EM, Arndt K, Falk M, et al. The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations. Curr Oncl 2023 Sep 27;30(10):8805-8814. doi:10.3390/curroncol30100635
Ortiz-Cuaran S, et al. Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors. Clin Canc Res 2016 Oct 1;22(19):4837-4847. doi:10.1158/1078-0432.CCR-15-1915